The combination of the B-raf proto-oncogene, serine/threonine kinase (BRAF) inhibitors and mitogen-activated extracellular signal-regulated kinase (MEK) inhibitors (BRAFi + MEKi) impeded the extracellular signal-regulated kinase 1/2 (ERK1/2) signaling cascade in melanoma cells, which induced the activation of caspase-3 and resulted in GSDME-executed pyroptosis as well as extravasation of DAMPs (132). The gene discussed is MAPK3; the disease is melanoma.